! HOT TOPIC - Time matters in AHF.
EUSEM Academy. PEACOCK F. 09/11/18; 227586; 38512 Topic: 1.3.4.2 Acute heart failure syndromes
Disclosure(s): Research Grants: Abbott, Braincheck, Immunarray, Janssen, Ortho Clinical Diagnostics, Relypsa, Roche, ZS Pharma
Consultant: Abbott, Astra-Zeneca, Bayer, Beckman, Boehrhinger-Ingelheim, Ischemia Care, Dx, Immunarray, Instrument Labs, Janssen, Ortho Clinical Diagnostics, Relypsa, Quidel, Roche, Siemens. Expert Testimony: Johnson and Johnson. Ownership Interests: AseptiScope, Inc., Comprehensive Research Associates LLC, Emergencies in Medicine LLC, Ischemia DX, LLC.
Prof. FRANK PEACOCK
Prof. FRANK PEACOCK
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
After viewing this presentation, the participant will be able to:
- Identify the time-dependent benefit of HF treatment
- Discuss the relative magnitude of the time to treatment and outcome effects in acute heart failure
- Adopt a strategy of rapid evaluation and treatment in suspected Acute Heart Failure patients presenting to the ER
After viewing this presentation, the participant will be able to:
- Identify the time-dependent benefit of HF treatment
- Discuss the relative magnitude of the time to treatment and outcome effects in acute heart failure
- Adopt a strategy of rapid evaluation and treatment in suspected Acute Heart Failure patients presenting to the ER
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies